New Developments in the 340B Drug Pricing Program
Recommended
New Developments in the 340B Drug Pricing Program
In this video, Adria Warren, health care transactional partner at Foley & Lardner LLP, spoke with the Journal of Clinical Pathways about new developments in the 340B drug pricing program and provided updates on recent court rulings and cases in process that may affect the program.
Access the full video and article to learn more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->